Stay updated with breaking news from Vp 102. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
This segment of Dr. Eichenfield’s interview featured a discussion about Eichenfield’s response to the FDA’s approval of cantharadin 0.7%, or VP-102, for molluscum contagiosum.
NEW YORK, June 11, 2022 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on...
SAN DIEGO, June 06, 2022 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, LLP announces that a class action lawsuit has commenced on...
Verrica Pharmaceuticals Inc. (VRCA) revealed that the U.S. Food and Drug Administration (FDA) extended the review period by three months for its New Drug Application (NDA) of VP-102 for the treatment of molluscum contagiosum (molluscum), a highly contagious viral skin disease. The Prescription Drug User Fee Act (PDUFA) goal date has also been postponed by three months to September 23, 2021. (See Verrica Pharmaceuticals stock analysis on TipRanks) The extension has provided the agency some additi